Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
Lukas Hartl(Medical University of Vienna), Michael Trauner(Medical University of Graz), Monika Breuer(Medical University of Vienna), Katharina Lampichler(Medical University of Vienna), Benedikt Simbrunner(Austrian Academy of Sciences), Katharina Haslinger(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Ahmed Ba‐Ssalamah(Medical University of Vienna), Emina Halilbasic(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Martin Angerer(Medical University of Vienna), Georg Semmler(Paracelsus Medical University), Robert Straßl(Medical University of Vienna), Mathias Schneeweiss‐Gleixner(Medical University of Vienna), Oliver Kimberger(Medical University of Vienna), Ernst Eigenbauer(Medical University of Vienna), Thomas Reiberger(Harvard University), Albert Friedrich Stättermayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Daniel Laxar(Medical University of Vienna), David Bauer(Austrian Academy of Sciences)
Cited by 74
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239